Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Osiris Therapeutics has concluded patient recruitment in a double-blind, placebo-controlled Phase 2 clinical trial investigating Prochymal (remestemcel-L).
Subscribe to our email newsletter
In the trial, the company will evaluate the safety and efficacy of Prochymal in conjunction with standard of care in improving heart function in patients who experienced their first heart attack.
In total, Osiris has recruited around 220 patients from 33 leading clinical centers in the United States and Canada.
Osiris Therapeutics senior vice president Lode Debrabandere said they look forward to following their progress and collecting high quality data on the safety and efficacy of Prochymal in this significant indication.